ECOR compared with GALT: revenue, margins and what each company keeps, and the suppliers and customers both name

ECORelectroCore, Inc.

Mkt capRevenueRevenue

GALTGalectin Therapeutics Inc

Mkt capRevenueRevenue

Compare

ECORelectroCore, Inc.

GALTGalectin Therapeutics Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ECOR1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+20.75%—

GALT1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±26.6%▼−2.55%×0.09

= impliedECOR realized, solidGALT realized, hatchedOne scale, both sides: full bar = 27%× = |realized| ÷ impliedSource: market data

ECORelectroCore, Inc.

7.02▼−1.94%

Mkt cap$67.8MRevenue$9MQ2 FY26Revenue$32MFY25

GALTGalectin Therapeutics Inc

3.43▲+3.13%

Regular sessionNov 3 '26

Mkt cap$335.8MRevenue—Revenue—

Compare

Regular sessionNov 3 '26

ECORelectroCore, Inc.

GALTGalectin Therapeutics Inc

7.02▼−1.94%

Price

3.43▲+3.13%

$67.8M

Mkt cap

$335.8M

Q2 FY26$9M

Revenue

—

FY25$32M

Revenue

—

ECOR7.02▼−1.94%vsGALT3.43▲+3.13%Regular sessionNov 3 '26